PMID- 33660212
OWN - NLM
STAT- MEDLINE
DCOM- 20211209
LR  - 20220119
IS  - 1559-0267 (Electronic)
IS  - 1080-0549 (Print)
IS  - 1080-0549 (Linking)
VI  - 61
IP  - 1
DP  - 2021 Aug
TI  - How Angioedema Quality of Life Questionnaire Can Help Physicians in Treating 
      C1-Inhibitor Deficiency Patients?
PG  - 50-59
LID - 10.1007/s12016-021-08850-9 [doi]
AB  - The Angioedema Quality of Life Questionnaire (AE-QoL) is an angioedema 
      (AE)-specific validated questionnaire, which surveys the quality of life of 
      diagnosed patients. The questionnaire has been used in multiple clinical trials. 
      Our aim was to investigate how the questionnaire can assist physicians in the 
      everyday practice of following up and managing C1-inhibitor deficiency patients. 
      In a prospective trial conducted in our center between 2016 and 2018, 125 
      hereditary angioedema and 10 diagnosed with acquired angioedema completed an 
      AE-QoL during their annual follow-up visit. Laboratory indices (i.e., complement 
      levels) were obtained for each patient. Statistical analysis comparing clinical 
      data with QoL parameters was performed. Results of the analysis show that AE-QoL 
      total score and number of AE attacks per year correlated well (r = 0.47; 
      p < 0.0001). Women reached higher AE-QoL total score values than men, over a 
      3-year period (p = 0.0014). The highest AE-QoL total scores were reached by the 
      41-60-year age group; we obtained a similar result, when analyzing the four 
      domains. No correlation was found between the AE-QoL total score and complement 
      parameters. Patients with a negative correlation between AE-QoL total score and 
      number of AE attacks had a positive correlation with psychologic attributes like 
      fatigue/mood and fears/shame domains. Patients that acquired HAE showed a 
      significant correlation between the annual number of AE attacks and the AE-QoL 
      total scores (r = 0.46; p < 0.0001). The study establishes the use of AE-QoL as a 
      clinical tool for follow-up which can help in the complex assessment of both 
      hereditary and acquired HAE patients, and help to develop better therapeutic 
      strategies.
CI  - (c) 2021. The Author(s).
FAU - Balla, Zsuzsanna
AU  - Balla Z
AUID- ORCID: 0000-0002-9041-5036
AD  - Hungarian Angioedema Center of Reference and Excellence, Department of Internal 
      Medicine and Haematology, Semmelweis University, Budapest, Hungary.
AD  - School of PhD Studies, Semmelweis University, Budapest, Hungary.
FAU - Ignacz, Bettina
AU  - Ignacz B
AD  - Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary.
FAU - Varga, Lilian
AU  - Varga L
AUID- ORCID: 0000-0002-5484-364X
AD  - Hungarian Angioedema Center of Reference and Excellence, Department of Internal 
      Medicine and Haematology, Semmelweis University, Budapest, Hungary.
FAU - Kohalmi, Kinga Viktoria
AU  - Kohalmi KV
AUID- ORCID: 0000-0002-7381-6866
AD  - Department of Internal Medicine and Haematology, Semmelweis University, Budapest, 
      Hungary.
AD  - Department of Rheumatology and Clinical Immunology, Semmelweis University, 
      Budapest, Hungary.
AD  - Department of Rheumatology, Hospital of the Hospitaller Brothers of Saint John of 
      God, Budapest, Hungary.
FAU - Farkas, Henriette
AU  - Farkas H
AUID- ORCID: 0000-0003-2929-1721
AD  - Hungarian Angioedema Center of Reference and Excellence, Department of Internal 
      Medicine and Haematology, Semmelweis University, Budapest, Hungary. 
      farkas.henriette@med.semmelweis-univ.hu.
LA  - eng
GR  - National Research, Development and Innovation Office grant N degrees  K124557./OTKA/
PT  - Journal Article
DEP - 20210303
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
SB  - IM
MH  - *Angioedema/diagnosis/epidemiology
MH  - *Angioedemas, Hereditary/diagnosis/therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - *Physicians
MH  - Prospective Studies
MH  - Quality of Life
MH  - Surveys and Questionnaires
PMC - PMC8282561
OTO - NOTNLM
OT  - Acquired angioedema
OT  - C1-inhibitor deficiency
OT  - Complement
OT  - Hereditary angioedema
OT  - Quality of life
OT  - Questionnaire
COIS- KVK-has received honoraria and travel grants from CSL Behring and Shire and has 
      participated in clinical trials of BioCryst, CSL Behring, Pharming and Shire. 
      LV-has received travel grants from CSL Behring and Shire Human Genetic Therapies 
      Inc. HF-received research grants from CSL Behring, Shire/Takeda and Pharming and 
      served as an advisor for these companies and Biocryst, and has participated in 
      clinical trials/registries for BioCryst, CSL Behring, Pharming, Kalvista and 
      Shire/Takeda. The other authors have declared that no conflict of interest 
      exists.
EDAT- 2021/03/05 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/03/03
CRDT- 2021/03/04 06:00
PHST- 2021/02/05 00:00 [accepted]
PHST- 2021/03/05 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/03/04 06:00 [entrez]
PHST- 2021/03/03 00:00 [pmc-release]
AID - 10.1007/s12016-021-08850-9 [pii]
AID - 8850 [pii]
AID - 10.1007/s12016-021-08850-9 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2021 Aug;61(1):50-59. doi: 10.1007/s12016-021-08850-9. 
      Epub 2021 Mar 3.